Hosted on MSN1h
AstraZeneca reports positive outcomes from breast cancer combo therapy trial
AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of ...
AstraZeneca’s Breast Cancer Drug Shows Positive Results In Late-Stage Trial
The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...
FierceBiotech1d
AstraZeneca, eyeing $5B peak sales, reports phase 3 breast cancer win for oral SERD
AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...
AstraZeneca therapy improves breast cancer survival in key trial
Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...
BioPharma Dive1d
AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch
The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...
PMLiVE1d
AstraZeneca’s camizestrant shows promise in phase 3 breast cancer study
The phase 3 SERENA-6 study randomised patients with HR-positive, HER2-negative advanced breast cancer whose tumours had an ...
BioSpace1d
AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Drug
In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...
AstraZeneca reports SERENA-6 trial shows improvement in the primary endpoint
Results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s (AZN) camizestrant in combination with a ...
pharmaphorum1d
Data cues up AZ oral SERD filing in first-line breast cancer
AstraZeneca could become the first company to bring an oral selective oestrogen receptor degrader (SERD) drug to market as a ...
AstraZeneca's camizestrant shows promise in breast cancer trial
AstraZeneca announced on Wednesday that its drug candidate camizestrant demonstrated a statistically significant and ...
AstraZeneca announces results from interim analysis of SERENA-6 Phase III trial
Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s (AZN) camizestrant in ...
AstraZeneca: Camizestrant Improved PFS in 1L HR+ Breast Cancer
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...